[1]
Thakkar JP,Dolecek TA,Horbinski C,Ostrom QT,Lightner DD,Barnholtz-Sloan JS,Villano JL, Epidemiologic and molecular prognostic review of glioblastoma. Cancer epidemiology, biomarkers [PubMed PMID: 25053711]
[2]
Ostrom QT,Gittleman H,Xu J,Kromer C,Wolinsky Y,Kruchko C,Barnholtz-Sloan JS, CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013. Neuro-oncology. 2016 Oct 1; [PubMed PMID: 28475809]
[3]
Kleihues P,Ohgaki H, Phenotype vs genotype in the evolution of astrocytic brain tumors. Toxicologic pathology. 2000 Jan-Feb; [PubMed PMID: 10669004]
[4]
Hodges LC,Smith JL,Garrett A,Tate S, Prevalence of glioblastoma multiforme in subjects with prior therapeutic radiation. The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses. 1992 Apr; [PubMed PMID: 1318344]
[5]
Wrensch M,Jenkins RB,Chang JS,Yeh RF,Xiao Y,Decker PA,Ballman KV,Berger M,Buckner JC,Chang S,Giannini C,Halder C,Kollmeyer TM,Kosel ML,LaChance DH,McCoy L,O'Neill BP,Patoka J,Pico AR,Prados M,Quesenberry C,Rice T,Rynearson AL,Smirnov I,Tihan T,Wiemels J,Yang P,Wiencke JK, Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nature genetics. 2009 Aug; [PubMed PMID: 19578366]
[6]
Brenner AV,Linet MS,Fine HA,Shapiro WR,Selker RG,Black PM,Inskip PD, History of allergies and autoimmune diseases and risk of brain tumors in adults. International journal of cancer. 2002 May 10; [PubMed PMID: 11979441]
[7]
Scheurer ME,Amirian ES,Davlin SL,Rice T,Wrensch M,Bondy ML, Effects of antihistamine and anti-inflammatory medication use on risk of specific glioma histologies. International journal of cancer. 2011 Nov 1; [PubMed PMID: 21190193]
[8]
Hochberg F,Toniolo P,Cole P,Salcman M, Nonoccupational risk indicators of glioblastoma in adults. Journal of neuro-oncology. 1990 Feb; [PubMed PMID: 2319291]
[9]
Urbańska K,Sokołowska J,Szmidt M,Sysa P, Glioblastoma multiforme - an overview. Contemporary oncology (Poznan, Poland). 2014; [PubMed PMID: 25477751]
[10]
Ostrom QT,Gittleman H,Farah P,Ondracek A,Chen Y,Wolinsky Y,Stroup NE,Kruchko C,Barnholtz-Sloan JS, CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro-oncology. 2013 Nov; [PubMed PMID: 24137015]
[11]
Ohgaki H,Dessen P,Jourde B,Horstmann S,Nishikawa T,Di Patre PL,Burkhard C,Schüler D,Probst-Hensch NM,Maiorka PC,Baeza N,Pisani P,Yonekawa Y,Yasargil MG,Lütolf UM,Kleihues P, Genetic pathways to glioblastoma: a population-based study. Cancer research. 2004 Oct 1; [PubMed PMID: 15466178]
[12]
Olar A,Aldape KD, Using the molecular classification of glioblastoma to inform personalized treatment. The Journal of pathology. 2014 Jan; [PubMed PMID: 24114756]
[13]
Stoyanov GS,Dzhenkov D,Ghenev P,Iliev B,Enchev Y,Tonchev AB, Cell biology of glioblastoma multiforme: from basic science to diagnosis and treatment. Medical oncology (Northwood, London, England). 2018 Jan 31; [PubMed PMID: 29387965]
[14]
Linkous AG,Yazlovitskaya EM, Angiogenesis in glioblastoma multiforme: navigating the maze. Anti-cancer agents in medicinal chemistry. 2011 Oct; [PubMed PMID: 21707499]
[15]
Agrawal A, Butterfly glioma of the corpus callosum. Journal of cancer research and therapeutics. 2009 Jan-Mar; [PubMed PMID: 19293489]
[16]
Katsetos CD,Dráberová E,Legido A,Dumontet C,Dráber P, Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin. Journal of cellular physiology. 2009 Dec; [PubMed PMID: 19650075]
[17]
Schultz S,Pinsky GS,Wu NC,Chamberlain MC,Rodrigo AS,Martin SE, Fine needle aspiration diagnosis of extracranial glioblastoma multiforme: Case report and review of the literature. CytoJournal. 2005 Nov 14; [PubMed PMID: 16287502]
[18]
Walker MD,Strike TA,Sheline GE, An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. International journal of radiation oncology, biology, physics. 1979 Oct; [PubMed PMID: 231022]
[19]
Chang CH,Horton J,Schoenfeld D,Salazer O,Perez-Tamayo R,Kramer S,Weinstein A,Nelson JS,Tsukada Y, Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer. 1983 Sep 15; [PubMed PMID: 6349785]
[20]
Cabrera AR,Kirkpatrick JP,Fiveash JB,Shih HA,Koay EJ,Lutz S,Petit J,Chao ST,Brown PD,Vogelbaum M,Reardon DA,Chakravarti A,Wen PY,Chang E, Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Practical radiation oncology. 2016 Jul-Aug; [PubMed PMID: 27211230]
[21]
Sneed PK,Lamborn KR,Larson DA,Prados MD,Malec MK,McDermott MW,Weaver KA,Phillips TL,Wara WM,Gutin PH, Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme. International journal of radiation oncology, biology, physics. 1996 Apr 1; [PubMed PMID: 8641924]
[22]
Koot RW,Maarouf M,Hulshof MC,Voges J,Treuer H,Koedooder C,Sturm V,Bosch DA, Brachytherapy: Results of two different therapy strategies for patients with primary glioblastoma multiforme. Cancer. 2000 Jun 15; [PubMed PMID: 10870063]
[23]
Hegi ME,Diserens AC,Gorlia T,Hamou MF,de Tribolet N,Weller M,Kros JM,Hainfellner JA,Mason W,Mariani L,Bromberg JE,Hau P,Mirimanoff RO,Cairncross JG,Janzer RC,Stupp R, MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England journal of medicine. 2005 Mar 10; [PubMed PMID: 15758010]
[24]
Stupp R,Mason WP,van den Bent MJ,Weller M,Fisher B,Taphoorn MJ,Belanger K,Brandes AA,Marosi C,Bogdahn U,Curschmann J,Janzer RC,Ludwin SK,Gorlia T,Allgeier A,Lacombe D,Cairncross JG,Eisenhauer E,Mirimanoff RO, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine. 2005 Mar 10; [PubMed PMID: 15758009]
[25]
Stupp R,Hegi ME,Mason WP,van den Bent MJ,Taphoorn MJ,Janzer RC,Ludwin SK,Allgeier A,Fisher B,Belanger K,Hau P,Brandes AA,Gijtenbeek J,Marosi C,Vecht CJ,Mokhtari K,Wesseling P,Villa S,Eisenhauer E,Gorlia T,Weller M,Lacombe D,Cairncross JG,Mirimanoff RO, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet. Oncology. 2009 May; [PubMed PMID: 19269895]
[26]
Taphoorn MJ,Stupp R,Coens C,Osoba D,Kortmann R,van den Bent MJ,Mason W,Mirimanoff RO,Baumert BG,Eisenhauer E,Forsyth P,Bottomley A, Health-related quality of life in patients with glioblastoma: a randomised controlled trial. The Lancet. Oncology. 2005 Dec; [PubMed PMID: 16321761]
[27]
Herrlinger U,Tzaridis T,Mack F,Steinbach JP,Schlegel U,Sabel M,Hau P,Kortmann RD,Krex D,Grauer O,Goldbrunner R,Schnell O,Bähr O,Uhl M,Seidel C,Tabatabai G,Kowalski T,Ringel F,Schmidt-Graf F,Suchorska B,Brehmer S,Weyerbrock A,Renovanz M,Bullinger L,Galldiks N,Vajkoczy P,Misch M,Vatter H,Stuplich M,Schäfer N,Kebir S,Weller J,Schaub C,Stummer W,Tonn JC,Simon M,Keil VC,Nelles M,Urbach H,Coenen M,Wick W,Weller M,Fimmers R,Schmid M,Hattingen E,Pietsch T,Coch C,Glas M, Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet (London, England). 2019 Feb 16; [PubMed PMID: 30782343]
[28]
Martínez-Garcia M,Álvarez-Linera J,Carrato C,Ley L,Luque R,Maldonado X,Martínez-Aguillo M,Navarro LM,Vaz-Salgado MA,Gil-Gil M, SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017). Clinical [PubMed PMID: 29086250]
[29]
Zarnett OJ,Sahgal A,Gosio J,Perry J,Berger MS,Chang S,Das S, Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis. JAMA neurology. 2015 May; [PubMed PMID: 25822375]
[30]
Herrlinger U,Schäfer N,Steinbach JP,Weyerbrock A,Hau P,Goldbrunner R,Friedrich F,Rohde V,Ringel F,Schlegel U,Sabel M,Ronellenfitsch MW,Uhl M,Maciaczyk J,Grau S,Schnell O,Hänel M,Krex D,Vajkoczy P,Gerlach R,Kortmann RD,Mehdorn M,Tüttenberg J,Mayer-Steinacker R,Fietkau R,Brehmer S,Mack F,Stuplich M,Kebir S,Kohnen R,Dunkl E,Leutgeb B,Proescholdt M,Pietsch T,Urbach H,Belka C,Stummer W,Glas M, Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 May 10; [PubMed PMID: 26976423]
[31]
Rao AM,Quddusi A,Shamim MS, The significance of MGMT methylation in Glioblastoma Multiforme prognosis. JPMA. The Journal of the Pakistan Medical Association. 2018 Jul; [PubMed PMID: 30317322]
[32]
Davis ME, Glioblastoma: Overview of Disease and Treatment. Clinical journal of oncology nursing. 2016 Oct 1; [PubMed PMID: 27668386]